Neumora Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 13, 2024, details the results of Neumora Therapeutics, Inc.'s Annual Meeting of Stockholders. The meeting was held on June 13, 2024, with a record date of April 15, 2024. As of the record date, 159,452,584 shares of common stock were outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two proposals, both of which were approved:
- Proposal 1: Election of Directors. Two Class I directors were elected to serve until the 2027 annual meeting.
- Henry O. Gosebruch: 88,190,874 votes For; 2,313,739 votes Withheld; 12,544,469 Broker Non-Votes.
- Kristina Burow: 87,022,169 votes For; 3,482,444 votes Withheld; 12,544,469 Broker Non-Votes.
- Proposal 2: Ratification of Auditors. Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Votes For: 102,921,992
- Votes Against: 123,868
- Abstentions: 3,222
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document serves solely to report the submission of matters to a vote of security holders.
Key Facts for Investor Verification
- Confirmation that Henry O. Gosebruch and Kristina Burow have officially joined the Board of Directors.
- Verification of the high level of broker non-votes (approx. 12.5 million shares) on the director election proposal.
- Confirmation that Ernst & Young LLP is the appointed auditor for the 2024 fiscal year.
- Review of the definitive proxy statement (Schedule 14A) filed on April 25, 2024, for detailed biographical information on nominees and further context on the proposals.